Table of Content

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview
4.1. Introduction
4.2. Oncology Biosimilars Market, by Region

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rapid approval by regulatory authorities for commercialization of products
5.1.1.2. Rising incidence of various types of cancers and leukemia
5.1.1.3. Recent innovation in clinical drug development
5.1.2. Restraints
5.1.2.1. High costs involved in the research
5.1.3. Opportunities
5.1.3.1. Introduction of new and innovative treatment options
5.1.3.2. Strategic alliances and investment for capacity expansion
5.1.4. Challenges
5.1.4.1. Limited clinical safety and efficacy data
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Oncology Biosimilars Market, by Application
6.1. Introduction
6.2. Cancer Treatment Drugs
6.3. Supportive Care Drugs

7. Oncology Biosimilars Market, by End-User
7.1. Introduction
7.2. Hospitals
7.3. Retail Pharmacies

8. Americas Oncology Biosimilars Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States

9. Asia-Pacific Oncology Biosimilars Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam

10. Europe, Middle East & Africa Oncology Biosimilars Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom

11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.2. Market Share Analysis, By Key Player
11.3. Competitive Scenario Analysis, By Key Player

12. Competitive Portfolio
12.1. Key Company Profiles
12.1.1. Allergan plc
12.1.2. Amneal Pharmaceuticals LLC.
12.1.3. Apotex Inc.
12.1.4. Aurobindo Pharma Limited
12.1.5. Bristol-Myers Squibb Company
12.1.6. Cipla Inc.
12.1.7. Eli Lilly and Company
12.1.8. Endo International plc
12.1.9. F. Hoffmann-La Roche Ltd.
12.1.10. GlaxoSmithKline plc
12.1.11. Glenmark Pharmaceuticals Limited
12.1.12. JSC BIOCAD
12.1.13. Lupin Limited
12.1.14. Mylan N.V.
12.1.15. Novartis AG
12.2. Key Product Portfolio

13. Appendix
13.1. Discussion Guide
13.2. License & Pricing



List of Figures

FIGURE 1. ONCOLOGY BIOSIMILARS MARKET RESEARCH PROCESS
FIGURE 2. ONCOLOGY BIOSIMILARS MARKET SIZE, 2023 VS 2030
FIGURE 3. ONCOLOGY BIOSIMILARS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. ONCOLOGY BIOSIMILARS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. ONCOLOGY BIOSIMILARS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. ONCOLOGY BIOSIMILARS MARKET DYNAMICS
FIGURE 7. ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 8. ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 10. ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. AMERICAS ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 12. AMERICAS ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. UNITED STATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 14. UNITED STATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. ASIA-PACIFIC ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. ASIA-PACIFIC ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. ONCOLOGY BIOSIMILARS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 20. ONCOLOGY BIOSIMILARS MARKET SHARE, BY KEY PLAYER, 2023

List of Tables

TABLE 1. ONCOLOGY BIOSIMILARS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018–2023
TABLE 3. ONCOLOGY BIOSIMILARS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 6. ONCOLOGY BIOSIMILARS MARKET SIZE, BY CANCER TREATMENT DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. ONCOLOGY BIOSIMILARS MARKET SIZE, BY SUPPORTIVE CARE DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 9. ONCOLOGY BIOSIMILARS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. ONCOLOGY BIOSIMILARS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. AMERICAS ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 12. AMERICAS ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 13. AMERICAS ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 14. ARGENTINA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 15. ARGENTINA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 16. BRAZIL ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 17. BRAZIL ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 18. CANADA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 19. CANADA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 20. MEXICO ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 21. MEXICO ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 22. UNITED STATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 23. UNITED STATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 24. UNITED STATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 25. ASIA-PACIFIC ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 26. ASIA-PACIFIC ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 27. ASIA-PACIFIC ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 28. AUSTRALIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 29. AUSTRALIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 30. CHINA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 31. CHINA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 32. INDIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 33. INDIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 34. INDONESIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 35. INDONESIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 36. JAPAN ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 37. JAPAN ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 38. MALAYSIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 39. MALAYSIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 40. PHILIPPINES ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 41. PHILIPPINES ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 42. SINGAPORE ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 43. SINGAPORE ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 44. SOUTH KOREA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 45. SOUTH KOREA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 46. TAIWAN ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 47. TAIWAN ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 48. THAILAND ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 49. THAILAND ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 50. VIETNAM ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 51. VIETNAM ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 52. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 53. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 54. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 55. DENMARK ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 56. DENMARK ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 57. EGYPT ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 58. EGYPT ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 59. FINLAND ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 60. FINLAND ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 61. FRANCE ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 62. FRANCE ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 63. GERMANY ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 64. GERMANY ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 65. ISRAEL ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 66. ISRAEL ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 67. ITALY ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 68. ITALY ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 69. NETHERLANDS ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 70. NETHERLANDS ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 71. NIGERIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 72. NIGERIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 73. NORWAY ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 74. NORWAY ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 75. POLAND ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 76. POLAND ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 77. QATAR ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 78. QATAR ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 79. RUSSIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 80. RUSSIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 81. SAUDI ARABIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 82. SAUDI ARABIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 83. SOUTH AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 84. SOUTH AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 85. SPAIN ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 86. SPAIN ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 87. SWEDEN ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 88. SWEDEN ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 89. SWITZERLAND ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 90. SWITZERLAND ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 91. TURKEY ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 92. TURKEY ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 93. UNITED ARAB EMIRATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 94. UNITED ARAB EMIRATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 95. UNITED KINGDOM ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 96. UNITED KINGDOM ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 97. ONCOLOGY BIOSIMILARS MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 98. ONCOLOGY BIOSIMILARS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 99. ONCOLOGY BIOSIMILARS MARKET LICENSE & PRICING